Current approved options for treating patients with multiple sclerosis

Syed A. Rizvi, Mark A. Agius

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Multiple sclerosis (MS), a neurologic disorder that affects 400,000 persons in the United States, consists of an inflammatory and a neurodegenerative phase. Treatment options now approved by the FDA specifically target the inflammatory phase of MS and include immunomodulators (i.e., interferon betas and glatiramer acetate) and an immuno-suppressant, mitoxantrone. This article discusses the methods of monitoring disease progression using disability scales and MRI and reviews the clinical efficacy and tolerability of the FDA-approved therapies. All of the immunomodulators are approved for the treatment of relapsing forms of MS, Only mitoxantrone is approved for the treatment of worsening relapsing-remitting MS, secondary progressive MS, and progressive-relapsing MS. Early treatment with these disease-modifying agents is desirable to reduce the progression of the disease and to limit long-term disability.

Original languageEnglish (US)
JournalNeurology
Volume63
Issue number12 SUPPL. 6
StatePublished - Dec 28 2004

Fingerprint

Multiple Sclerosis
Chronic Progressive Multiple Sclerosis
Mitoxantrone
Immunologic Factors
Disease Progression
Therapeutics
Relapsing-Remitting Multiple Sclerosis
Interferon-beta
Nervous System Diseases

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Rizvi, S. A., & Agius, M. A. (2004). Current approved options for treating patients with multiple sclerosis. Neurology, 63(12 SUPPL. 6).

Current approved options for treating patients with multiple sclerosis. / Rizvi, Syed A.; Agius, Mark A.

In: Neurology, Vol. 63, No. 12 SUPPL. 6, 28.12.2004.

Research output: Contribution to journalArticle

Rizvi, SA & Agius, MA 2004, 'Current approved options for treating patients with multiple sclerosis', Neurology, vol. 63, no. 12 SUPPL. 6.
Rizvi, Syed A. ; Agius, Mark A. / Current approved options for treating patients with multiple sclerosis. In: Neurology. 2004 ; Vol. 63, No. 12 SUPPL. 6.
@article{7760f201a2454208b2c6b64c7d3313fa,
title = "Current approved options for treating patients with multiple sclerosis",
abstract = "Multiple sclerosis (MS), a neurologic disorder that affects 400,000 persons in the United States, consists of an inflammatory and a neurodegenerative phase. Treatment options now approved by the FDA specifically target the inflammatory phase of MS and include immunomodulators (i.e., interferon betas and glatiramer acetate) and an immuno-suppressant, mitoxantrone. This article discusses the methods of monitoring disease progression using disability scales and MRI and reviews the clinical efficacy and tolerability of the FDA-approved therapies. All of the immunomodulators are approved for the treatment of relapsing forms of MS, Only mitoxantrone is approved for the treatment of worsening relapsing-remitting MS, secondary progressive MS, and progressive-relapsing MS. Early treatment with these disease-modifying agents is desirable to reduce the progression of the disease and to limit long-term disability.",
author = "Rizvi, {Syed A.} and Agius, {Mark A.}",
year = "2004",
month = "12",
day = "28",
language = "English (US)",
volume = "63",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "12 SUPPL. 6",

}

TY - JOUR

T1 - Current approved options for treating patients with multiple sclerosis

AU - Rizvi, Syed A.

AU - Agius, Mark A.

PY - 2004/12/28

Y1 - 2004/12/28

N2 - Multiple sclerosis (MS), a neurologic disorder that affects 400,000 persons in the United States, consists of an inflammatory and a neurodegenerative phase. Treatment options now approved by the FDA specifically target the inflammatory phase of MS and include immunomodulators (i.e., interferon betas and glatiramer acetate) and an immuno-suppressant, mitoxantrone. This article discusses the methods of monitoring disease progression using disability scales and MRI and reviews the clinical efficacy and tolerability of the FDA-approved therapies. All of the immunomodulators are approved for the treatment of relapsing forms of MS, Only mitoxantrone is approved for the treatment of worsening relapsing-remitting MS, secondary progressive MS, and progressive-relapsing MS. Early treatment with these disease-modifying agents is desirable to reduce the progression of the disease and to limit long-term disability.

AB - Multiple sclerosis (MS), a neurologic disorder that affects 400,000 persons in the United States, consists of an inflammatory and a neurodegenerative phase. Treatment options now approved by the FDA specifically target the inflammatory phase of MS and include immunomodulators (i.e., interferon betas and glatiramer acetate) and an immuno-suppressant, mitoxantrone. This article discusses the methods of monitoring disease progression using disability scales and MRI and reviews the clinical efficacy and tolerability of the FDA-approved therapies. All of the immunomodulators are approved for the treatment of relapsing forms of MS, Only mitoxantrone is approved for the treatment of worsening relapsing-remitting MS, secondary progressive MS, and progressive-relapsing MS. Early treatment with these disease-modifying agents is desirable to reduce the progression of the disease and to limit long-term disability.

UR - http://www.scopus.com/inward/record.url?scp=10944261736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10944261736&partnerID=8YFLogxK

M3 - Article

C2 - 15623672

AN - SCOPUS:10944261736

VL - 63

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 12 SUPPL. 6

ER -